Activated Factor Seven in Traumatic Retro Peritoneal Hematoma
NCT ID: NCT04424563
Last Updated: 2020-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2017-05-05
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy of Early Bunching of a FF-PCC in Patients With Severe Traumatic Hemorrhage
NCT05738642
Factor In the Initial Resuscitation of Severe Trauma 2 Patients
NCT04534751
Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy
NCT06582420
The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry
NCT00328133
Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion
NCT07290634
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
King Abdelaziz research and ethical committee approved the project under heading of ethical approval and heading of human and animal rights along with Helsinki Declaration.
A written consent from the patient or from their 1st degree relative was obtained if patient intubated. The primary outcome of This study divided into 3 parts. 1st 0ne compare the ability of both drugs to stop retroperitoneal bleeding efficiently and in shorter time for these 2 measurable indicators selected in our study the number of packed RBCS needed to achieve hemoglobin level (Hb) \> 10 gm% and the time needed to achieve this target Hb. the 2nd part indicators divided into clinical indicators (blood pressure, pulse and urine output) and laboratory indicators \[arterial blood gases especially PH, and bicarbonate concentration (HCO3)\]. the 3rd part indicators PT, PTT and Platelets count were used as indicator for DIC and hypoxic index and chest x ray were used as indicator for TRALI (transfusion related acute lung injury).
Resuscitation done in all patients in both groups according to hospital protocol by crystalloid (normal saline), colloids \[plasma protein fraction-packed RBCs, fresh frozen plasma\], until achieve satisfactory stable vital data. All laboratory work samples were collected (CBC complete blood picture, Blood chemistry included liver enzymes and kidney function tests, Coagulation profile, arterial blood gasses).
Urine output collected hourly. Our study included any patient who received more than 50ml/kg blood during the first 8hours after admission in order to achieved a hemoglobin level \>10 gram %, with platelet count more than 50, 000/mm3 after resuscitation and Their temperature was more than 36 degree centigrade after warming. Which considered criteria needed to get maximum effect from aFVII if used intravenously. Patient randomized into 2 groups, 40 patients in each, this done by randomization numbers. Patients of group A received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours. While patients of group B received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed. The exclusion criteria in our study, if patient had cardiac arrest before giving aFVII, deeply comatose with Glasgow coma scale (GCS) 3/15 and pupil dilated fixed.
All patient in both groups observed for 48hours and the following indicators recorded.
Indicators for efficacy of stop bleeding (number of packed RBCs needed to keep hemoglobin level \>10 gm% and time needed to reach this target Hb).
Indicators for ability of both drugs to treatment the hemorrhagic shock and restore tissue perfusion (and this assessed by clinical indicators blood pressure, pulse and urine output and laboratory indicators as arterial PH and bicarbonate concentration ( HCO3) Indicators for ability of both drugs to protect the patients with retroperitoneal hematoma from complications of massive blood transfusion and in this 2 complications were selected the disseminated intra-vascular coagulopathy (DIC) and PT, PTT, Platelets count were used as indicators and (TRALI) transfusion related acute lung injury and the hypoxic index and chest x ray were used as indicators. The duration of the study only two days and the data recorded every 8 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Patients of group A include 40 patients, received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
ventilators
all patients in both groups will be ventilated if shocked and no recordable blood pressure
aminocaproic acid
4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
Group B
While patients of group B include 40 patients, received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed.
ventilators
all patients in both groups will be ventilated if shocked and no recordable blood pressure
Novo Seven
200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ventilators
all patients in both groups will be ventilated if shocked and no recordable blood pressure
aminocaproic acid
4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
Novo Seven
200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Abdul Aziz Specialist Hospital
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King abd el Aziz specialist hospital
Ta'if, , Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICU-8-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.